This report contains market size and forecasts of Ultra Short Acting Insulin in global, including the following market information:
Global Ultra Short Acting Insulin Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global Ultra Short Acting Insulin Market Sales, 2017-2022, 2023-2028, (K Units)
Global top five Ultra Short Acting Insulin companies in 2021 (%)
The global Ultra Short Acting Insulin market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period 2022-2028.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Insulin Lispro Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Ultra Short Acting Insulin include Eli Lilly and Company, Gan & Lee Pharmaceuticals, Novo Nordisk, Wockhardt, Ypsomed, Tonghua Dongbao, Sanofi, United Laboratory and Jiangsu Wanbang, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Ultra Short Acting Insulin manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Ultra Short Acting Insulin Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Ultra Short Acting Insulin Market Segment Percentages, by Type, 2021 (%)
Insulin Lispro
Insulin Aspart
Insulin Glulisine
Global Ultra Short Acting Insulin Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Ultra Short Acting Insulin Market Segment Percentages, by Application, 2021 (%)
Type 1 Diabetes
Type 2 Diabetes
Gestational Diabetes
Global Ultra Short Acting Insulin Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Ultra Short Acting Insulin Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Ultra Short Acting Insulin revenues in global market, 2017-2022 (Estimated), ($ millions)
Key companies Ultra Short Acting Insulin revenues share in global market, 2021 (%)
Key companies Ultra Short Acting Insulin sales in global market, 2017-2022 (Estimated), (K Units)
Key companies Ultra Short Acting Insulin sales share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Eli Lilly and Company
Gan & Lee Pharmaceuticals
Novo Nordisk
Wockhardt
Ypsomed
Tonghua Dongbao
Sanofi
United Laboratory
Jiangsu Wanbang
B. Braun
Becton, Dickinson
Biocon
Biodel